The SCID-hu Myeloma Model
The severe combined immune deficient human (SCID-hu) myeloma model is the only available model in which primary myeloma cells grow in vivo in a human bone marrow microenvironment. A SCID mouse receives an implanted human fetal bone into which myeloma cells are directly injected. Through interaction with the human bone marrow microenvironment, the myeloma cells induce typical myeloma manifestations in the SCID host, such as the appearance of M protein in the serum, and changes in the implanted human bone, which often result in osteolysis of the human bone. The model provides the only platform for in vivo investigation of the biology and therapy of primary human myeloma in a human microenvironment. This chapter describes in detail all the steps necessary to establish this model and evaluate its success.
- Relationship of EGFR Signal-Transduction Modulation by Tyrosine Kinase Inhibitors to Chemosensitivity and Programmed Cell Death
- Detection of K-ras Point Mutations in Sputum from Patients with Adenocarcinoma of the Lung by Point-EXACCT
- Genetic Manipulation of Yeast to Identify Genes Involved in Regulation of Chemosensitivity
- Transforming Growth Factor Beta: A Plasma Tumor Marker
- Purification of Annexin V and Its Use in the Detection of Apoptotic Cells
- Gold Nanocages for Cancer Imaging and Therapy
- 99mTc-Annexin A5 Uptake and Imaging to Monitor Chemosensitivity
- 测定细胞内钙离子浓度的方法
- A Nested RT-PCR Assay to Detect BCR/abl
- Measuring Cyclin-Dependent Kinase Activity